Abstract
There is an urgent need for new antibiotics and alternative strategies to combat bacterial pathogens. Molecular docking, antibacterial evaluation in vitro and in vivo, cytotoxicity assessment and enzyme inhibition analyses were performed. Compound 12 exhibited antimicrobial activity against Staphylococcus aureus (MIC: 4μg/ml), various clinically isolated strains of MRSA (MIC: 4-16μg/ml) and Acinetobacter baumannii (MIC: 4μg/ml) when combined with subinhibitory concentrations of colistin B. Compound 12 (20mg/kg) yielded mild improvement in survival ofmethicillin-resistant Staphylococcus aureus(MRSA)-infected mice. Additionally, enzyme inhibition tests showed that compound 12 exhibited inhibitory effects against S. aureus dihydrofolate reductase (105.1μg/ml) and DNA gyrase (122.8μg/ml). Compound 12 is a promising antibacterial candidate for further development.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
